Skip to main content
logo
/
Aerovate Therapeutics, Inc. (AVTE)
9.80
0.00 (0.00%)
Inactive · Last trade price on Apr 28, 2025

Company Description

Aerovate Therapeutics, Inc., a biopharmaceutical company, engages in the treatment of pulmonary arterial hypertension in the United States. Aerovate Therapeutics, Inc., was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Aerovate Therapeutics, Inc.
Aerovate Therapeutics logo
CountryUnited States
Founded2018
IPO DateJun 30, 2021
IndustryBiotechnology
SectorHealthcare
Employees30
CEOTimothy Noyes

Contact Details

Address:
930 Winter Street, Suite M-500
Waltham, Massachusetts 02451
United States
Phone617 443 2400
Websiteaerovatetx.com

Stock Details

Ticker SymbolAVTE
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
IPO Price$14.00
CIK Code0001798749
CUSIP Number008064107
ISIN NumberUS0080641071
Employer ID83-1377888
SIC Code2834

Key Executives

NamePosition
Timothy P. Noyes M.B.A.Chief Executive Officer and Director
George A. EldridgeChief Financial Officer and Treasurer
Dr. Benjamin T. Dake Ph.D.Founder, President, Chief Operating Officer and Secretary
Dr. Ralph W. Niven M.B.A., M.R, Ph.D., Pharm.SChief Scientific Officer
Hunter Gillies M.D.Chief Medical Officer
Donna DeaHead of Regulatory Affairs
Susan FischerExecutive Vice President of Development Operations
Stephen K. YuSenior Vice President of Quality
Dr. Sanjeev KhindriExecutive Vice President of Clinical Development
Dr. Cheryl Lassen BSc., M.D., MBBChSenior Vice President of Clinical Development

Latest SEC Filings

DateTypeTitle
Apr 25, 202510-QQuarterly Report
Apr 23, 20258-KCurrent Report
Apr 21, 20258-KCurrent Report
Apr 9, 2025425Filing
Apr 9, 2025425Filing
Apr 9, 20258-KCurrent Report
Apr 9, 2025425Filing
Apr 9, 20258-KCurrent Report
Apr 7, 2025425Filing
Apr 7, 2025425Filing
View All SEC Filings